SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Dogecoin is an open-source digital currency based on the "Doge" meme that functions as a peer-to-peer medium for fast payments and digital tipping. Unlike projects backed by corporate entities, its value is driven by a global community, and the project is managed by a decentralized group of volunteers and the non-profit Dogecoin Foundation rather than a formal company.  Originally created in 2013 by software engineers Billy Markus and Jackson Palmer as a market parody, the project held no public sale or venture capital rounds. The network operates as a fork of LuckyCoin, which itself was a fork of Litecoin, using a proof of work consensus mechanism. It employs the Scrypt algorithm to ensure the mining process remains fast and efficient, with new blocks processed every 60 seconds. A unique technical feature is its use of merged mining, allowing miners to secure Dogecoin simultaneously with other Scrypt-based networks like Litecoin.  To keep transaction fees low and the network running indefinitely, Dogecoin features an uncapped supply where new coins are added forever. In a major regulatory milestone in March 2026, a joint SEC and CFTC framework officially classified Dogecoin as a digital commodity, placing it in the same asset category as gold or oil.

Dogecoin

Dogecoin is currently experiencing high volatility, with the community actively debating whether it remains a viable meme coin leader or is merely a stagnant asset, all while market participants closely watch Bitcoin's price action for potential momentum shifts. Discussions are heavily fueled by speculative hopes for a breakthrough rally and frustration among long-term holders waiting for a sustained upward trend.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bear 3X ETF

Direxion Daily Semiconductor Bear 3X Shares

The Direxion Daily Semiconductor Bear 3X Shares (SOXS) is seeing heavy social media volume as traders debate whether the semiconductor sector's record-breaking win streak is nearing a parabolic peak or represents an unbreakable AI-driven super cycle. Community members are actively sharing their high-conviction positions and frustration over the instrument's significant decay, while others continue to debate the timing of a potential sector-wide pullback.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

The semiconductor sector is currently experiencing historic, parabolic growth, fueling intense community debate over whether this represents a sustainable AI-driven super cycle or a bubble nearing a blow-off top. Investors are actively watching earnings reports and geopolitical tensions as key catalysts, with high-conviction bulls adding to leveraged positions while some market observers warn that extreme technical indicators suggest an imminent pullback.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network is trending as investors aggressively accumulate in anticipation of upcoming announcements and the project's featured presence at the XRP Las Vegas conference. Community sentiment remains polarized, with long-term holders emphasizing patience and potential utility-driven growth, while others debate the impact of volatility and market speculation.

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is currently a focal point for investors as the company's Phase 3 readout for its gene-editing therapy approaches, fueling intense speculation about a potential short squeeze given the high level of short interest. The community is actively debating the reliability of clinical trial designs and the broader implications for the gene-editing sector, with many participants watching closely for how the impending data will move the stock.

X-Energy, Inc. operates as an energy company The firm focuses on modular nuclear reactors and fuel technology for clean energy generation. The company was founded by Kam Ghaffarian and Eben Mulder on 2009 and is headquartered in Rockville, MD.

X-Energy Inc. - Ordinary Shares- Class A

X-energy Inc

X-energy (XE) is surging following its highly anticipated IPO, with investors heavily focused on its strategic backing from Amazon and its potential role in powering AI data centers. The community is actively debating the stock's valuation relative to SMR peers while tracking high institutional interest and strong demand that exceeded initial expectations.

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is trending as the community doubles down on the project, pushing back against recent volatility and negative sentiment by highlighting ongoing development and a long-term shift toward utility and AI-focused business management. Holders are actively discussing their commitment to the project, emphasizing the importance of community perseverance and a 'build-it' mentality while dismissing concerns regarding project viability.

PENGU is the official coin of Pudgy Penguins.  Pudgy Penguins has become the face of crypto with one of the most influential communities in the industry. From large companies wearing the Penguin, to being featured in ETF commercials, to garnering millions of followers and over 100 billion views, the Pengu has become a cultural icon making PENGU the world’s social currency.  PENGU allows for the ever-expanding Pudgy Penguin fanbase and the hundreds of millions of people outside of crypto that see and share the Pudgy Penguin everyday, to join The Huddle. PENGU is a symbol for community, memes, and good vibes.  Believe in Pengu. Believe in the Prophecy.

Pudgy Penguins

Pudgy Penguins (PENGU) is generating buzz as investors monitor its transition from an NFT-based brand to a "phygital" ecosystem with physical toy sales and potential retail expansion. The community remains divided between long-term holders accumulating shares amidst price volatility and skeptics comparing its recent performance to other speculative meme coins.

What is the project about? Pepe is a community based meme token surround the iconic meme Pepe the frog. Pepe aims to leverage the power of such an iconic meme to become the most memeable memecoin in existence.   What makes your project unique? Pepe is here to make memecoins great again. Ushering in a new paradigm for memecoins, Pepe represents the memecoin in it's purest simplicity. With zero taxes, liquidity locked forever, and contract immutable, Pepe is for the people, forever. Pepe is about culture, rallying together a community to have fun and enjoy memes, fueled purely by memetic power.   History of your project. Pepe was stealth launched on Friday, April 14th, 2023.   What’s next for your project? Pepe will focus on developing a tight-knit community around the token and building resources to enrich the communities knowledge and success in crypto through a token gated group, newsletter, and more tools.   What can your token be used for? Pepe can be used to speculate on the power of memes, and does not pretend to be anything more.

Pepe

Pepe is currently capturing significant community attention as traders closely monitor technical resistance levels and look for a breakthrough above the key four-cent barrier. The coin remains a central focus of speculative discussions as the broader meme sector searches for renewed volume and momentum during ongoing market volatility.

The White Alien has arrived. The countdown to domination starts now.

The White Alien

The White Alien is generating significant social media momentum as investors link the asset to trending community narratives and cross-promote it alongside other speculative digital tokens. Market participants are actively engaging with the coin's viral persona, fueling discussions centered on community-driven growth and high-volatility momentum.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Sagimet Names Andreas Grauer CMO

(RTTNews) - Sagimet Biosciences Inc. (SGMT), on Monday announced the appointment of Andreas Grauer as Chief Medical Officer, effective April 20...

Sagimet Biosciences Inc. (NASDAQ:SGMT) Short Interest Down 15.2% in March

Sagimet Biosciences Inc. (NASDAQ:SGMT - Get Free Report) saw a significant decrease in short interest in March. As of March 31st, there was short interest totaling 3,225,311 shares, a decrease of...

Sagimet Biosciences Inc. (NASDAQ:SGMT) Receives Consensus Rating of "Moderate Buy" from Analysts

Shares of Sagimet Biosciences Inc. (NASDAQ:SGMT - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the eleven brokerages that are currently covering the firm...

Sagimet Biosciences (NASDAQ:SGMT) Now Covered by Rodman & Renshaw

Rodman & Renshaw assumed coverage on shares of Sagimet Biosciences in a research report on Thursday. They set a "buy" rating and a $28.00 price objective for the company...

Sagimet Biosciences (SGMT) Expected to Announce Quarterly Earnings on Monday

Sagimet Biosciences (NASDAQ:SGMT) will be releasing its Q4 2025 earnings on Monday, March 30. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-3-30-sagimet-biosciences-inc-series-a-stock...

HC Wainwright Has Negative Outlook for SGMT FY2027 Earnings

Sagimet Biosciences Inc. (NASDAQ:SGMT - Free Report) - Analysts at HC Wainwright dropped their FY2027 earnings per share (EPS) estimates for Sagimet Biosciences in a report issued on Wednesday, March...

Sagimet Biosciences (NASDAQ:SGMT) Upgraded to "Hold" at Wall Street Zen

Wall Street Zen raised Sagimet Biosciences from a "sell" rating to a "hold" rating in a research note on Saturday...

Q1 Earnings Forecast for SGMT Issued By HC Wainwright

Sagimet Biosciences Inc. (NASDAQ:SGMT - Free Report) - Equities researchers at HC Wainwright issued their Q1 2026 earnings per share estimates for Sagimet Biosciences in a research report issued on...

Sagimet Biosciences (NASDAQ:SGMT) Receives Buy Rating from HC Wainwright

HC Wainwright restated a "buy" rating and set a $29.00 price target on shares of Sagimet Biosciences in a research note on Wednesday...

Sagimet Biosciences (NASDAQ:SGMT) Issues Earnings Results

Sagimet Biosciences (NASDAQ:SGMT - Get Free Report) issued its quarterly earnings results on Wednesday. The company reported ($0.30) EPS for the quarter, beating analysts' consensus estimates of...

Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for the treatment of infectious diseases. Its lead drug candidate, denifanstat, is an oral, once-daily pill and selective fatty acid synthase (FASN) inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH). The company was founded by Urs F. Greber, Ari Helenius, and Lucas Pelkmans on December 19, 2006 and is headquartered in San Mateo, CA.

Current Price	$5.86
Prev Close	$5.87
Open	$5.85
Dividend Yield	0.00%
50-Day Moving Average	$5.43
Beta	0.00
Avg. Volume	365,397.59
PE Ratio	-3.71

52-Week High	$11.41
52-Week Low	$3.03
Market Capitalization	$187.62M
EPS (Annual)	-$1.58
Price to Book	1.71
Revenue Per Employee	$0.00

SGMT
Sagimet Biosciences Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SGMT News

SGMTSagimet Biosciences Inc